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Factorial designAbstract In the current study zidovudine loaded PLGA nanoparticles were prepared, coated and
further investigated for its effectiveness in brain targeting. IR and DSC studies were performed to
determine the interaction between excipients used and to ﬁnd out the nature of drug in the formu-
lation. Formulations were prepared by adopting 23 factorial designs to evaluate the effects of pro-
cess and formulation variables. The prepared formulations were subjected for in vitro and in vivo
evaluations. In vitro evaluations showed particle size below 100 nm, entrapment efﬁciency of formu-
lations ranges of 28–57%, process yield of 60–76% was achieved and drug release for the formula-
tions were in the range of 50–85%. The drug release from the formulations was found to follow
Higuchi release pattern, n–value obtained after Korsemeyer plot was in the range of 0.56–0.78.
In vivo evaluations were performed in mice after intraperitoneal administration of zidovudine drug
solution, uncoated and coated formulation. Formulation when coated with Tween 80 achieved a
higher concentration in the brain than that of the drug in solution and of the uncoated formulation.
Stability studies indicated that there was no degradation of the drug in the formulation after 90 days
of preparation when stored in refrigerated condition.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
HIV reaches and infects the central nervous system soon after
entering the host followed by the establishment of a viral res-
ervoir which produces complex neurological problems, latent
infections and resistance (Wong et al., 2010). Main reason
for Human Immuno Deﬁciency Virus (HIV) to infect and
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and replicate at siteswhere there is low concentration of circulat-
ing antibodies as these virus strains are susceptible for neutral-
ization by host antibodies (Kolchinsky et al., 2001). Usually
HIV and other infectious organisms gain access to the brain
by adopting two pathways Transcellular and paracellular path-
way and/or Trojan horse mechanism Micro organisms use any
one of these approaches or a combination of these approaches
to access CNSwhichmainly depends on the nature of the organ-
ism (Huang and Jong, 2001). HIV invades the central nervous
system (CNS) after peripheral infection, Highly Active Anti
Retroviral Therapy (HAART) is unlikely to prevent the entry
ofHIV into theCNS.HIV-infectedmonocytes in the circulatory
system can permeate the blood–brain barrier and thus cause
infection in the CNS. It has been observed from previous studies
that the pathological features of HIV-1 infection in the brain
lead to widespread activation of macrophages, microglial nod-
ules, activated resident microglia, astrocytes, myelin pallor,
multinucleated giant cells and blood-derived macrophages
(Fischer-Smith and Rappaport, 2005).
The drug used in the study zidovudine was classiﬁed under the
antiretroviral category and these classes of drugs are active against
a anti retro virus such as HIV. These drugs prolong and improve
the quality of life by suppressing many complications associated
with AIDS. Zidovudine increases CD4 counts and reduces HIV
RNAtoundetectable levels and this results in good immune status,
reduces opportunistic infections, also reduces mortality rate, sup-
presses the occurrence of newKaposis lesions, and reduces neuro-
logical manifestations of AIDS. It is also found to slowdown the
progress of the disease (Tripathi, 2008).
PLGA possess ES good CNS biocompatibility, which was
proved in many studies (Emerich et al., 1999; Menei et al.,
1993). Devices and formulations made of PLGA nanoparticles
are available in Europe, Japan, and the US (Ueda and Tabata,
2003). The importance of incorporating Quality by Design is
recognized and implemented now days, by USFDA and other
regulatory agencies worldwide, ICH has issued guidance that
describes the implementation of Quality by Design in various
stages of product development. ICH Q8 has given a full
description about the use of some tools for the design of the
experiment and its implementation for various applications
in pharmaceutical manufacturing (ICH, 2008). The objective
of the study is to develop tween 80 coated zidovudine loaded
PLGA nanoparticles to achieve good concentration of the
drug in the brain. To obtain this objective formulations were
prepared using nanoprecipitation technique. 23 factorial design
was adopted in preparing formulations. The coating of tween
80 on prepared formulations was achieved by the adsorption
method. The formulations were evaluated in vitro to evaluate
all physico chemical and release parameters. Brain availability
and tissue distribution studies for the prepared formulations
were studied by using mice.
2. Materials and methods
2.1. Materials
Zidovudine was gifted by Alembic Pharma Gujarat, Poly (Lac-
tic-co-glycolic acid) PLGA
50:50 Ratio Molecular weight 7000–17,000, was purchased
from Sigma Aldrich chemicals Pvt. Ltd., USA, Tween 80 waspurchased from Loba Chemie Pvt. Ltd., Mumbai, Poloxamer
407 was purchased from Sigma Aldrich chemicals Pvt. Ltd.,
USA, Dialysis membrane was purchased from HiMedia Labo-
ratories Pvt. Ltd. Mumbai, Methanol HPLC Grade was pur-
chased from Thermo Fisher Scientiﬁc Ind. Pvt. Ltd.
Mumbai, Acetonitrile HPLC Grade was purchased from
Ranbaxy Fine Chemicals Ltd., Mumbai, Water HPLC Grade
was purchased from Ranbaxy Fine Chemicals Ltd., Mumbai.
2.2. Methods
2.2.1. Experimental design
Formulation design adopted in the study was the 23 factorial
design. The dependant and independent variables of the design
are shown below.
Independent variable Levels Dependent variable
Low High
Polymer 100 200 Particle size
Poloxamer 50 100 Entrapment eﬃciency
pH of aqueous phase 1.2 Neutral In vitro releaseThe formulation design was generated by using Design Ex-
pert Software (Version 8.0).
2.2.2. Differential scanning calorimetry studies for zidovudine
formulations
DSC studies were performed to assess the presence and nature
of the encapsulated drug in formulations and also to study the
interaction between excipients used, DSC studies were carried
out in NETZSCH DSC 204. The samples were loaded in the
chamber and gradually heated till 300 C with a heating rate
of 10 C/min.
2.2.3. Preparation of zidovudine loaded PLGA nanoparticles by
nanoprecipitation technique
Organic phase was prepared by dissolving weighed quantities
of drug and polymer in 4 ml acetone. The aqueous phase
was prepared by dissolving a weighed quantity of poloxamer
in water. Then the organic phase was poured into the aqueous
phase and stirred constantly using a magnetic stirrer at
100 RPM. The stirring is continued for 4 h till complete evap-
oration of the organic solvent (Fessi et al., 1989). The formu-
lation composition is summarized in Table 1.
The prepared nanoparticles were suspended in PBS 7.4 and
tween 80 was added to the suspended nanoparticles to give a
concentration of 1% and incubated for 1 h (Wilson et al., 2008).
2.2.4. Evaluation of nanoparticles
2.2.4.1. Particle size determination. Mean particle size of the
prepared nanoparticles was determined by phase contrast
microscope (PCM). The prepared samples were placed on a
slide and images were taken by using a Leica Inverted Phase
Contrast Microscope (Leica S 40, 230 ± 10v, 5 W). Average
particle sizes of 50 particles were measured and mean particle
size was calculated.
2.2.4.2. Surface morphology. Surface characteristics of the for-
mulation F9 were analyzed by performing HR TEM analysis.
Table 1 Formulation table showing the composition of zidovudine, PLGA, and poloxamer 407.
Formulation code Zidovudine (mg) PLGA (mg) Poloxamer 407 (mg) Aqueous medium
F1 100 100 50 PH 1.2
F2 100 200 50 PH 1.2
F3 100 100 100 PH 1.2
F4 100 200 100 PH 1.2
F5 100 100 50 Distilled water
F6 100 200 50 Distilled water
F7 100 100 100 Distilled water
F8 100 200 100 Distilled water
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per grid, and a drop of the prepared formulation is placed on
the grid and dried. The dried samples were placed in HR TEM
analyzer JEOL TEM 2100 and images were taken.
2.2.4.3. Surface charge. Surface charge of the coated formula-
tion F9 was determined by using Malvern Zeta sizer ZS90. The
formulations were placed on the instrument and the surface
charge was determined.
2.2.4.4. Entrapment efﬁciency. The nanoformulations were cen-
trifuged and the supernatant containing free drug was collected
which was further analyzed by UV at 266 nm. This gives the
amount of drug that is unentrapped in the nanoparticles.
Amount of drug found in the supernatant was subtracted from
the total amount of drug added to the formulation which gives
the amount of drug entrapped in the nanoparticles (Govender
et al., 1999). The formulations were evaluated for entrapment
efﬁciency by the following formula
¼Mass of drug in nanoparticles 100
Mass of drug used in formulation2.2.4.5. Process yield. The yield of nanoparticles were calcu-
lated using the following equation
Yield ¼ Mass of nanoparticles recovered 100
Mass of polymerþ drugþ other excipients2.2.4.6. In vitro release study. The release studies were carried
out by using the dialysis membrane technique where the dialysis
bag with a molecular weight cut off of 12,000–14,000 was used.
The membrane was pretreated with warm phosphate buffer sal-
ine for 10 min. Then 50 mgof the prepared formulation and 1 ml
of PBS were added into the dialysis bag and then immersed into
50 ml of phosphate buffered saline medium (pH 7.4). Stirring
was performed at 100 RPM by using a magnetic stirrer at
37 C. Samples (2 ml) were withdrawn at various time points
and equal volume of fresh buffer is replaced and the absorbance
was measured by a UV spectrophotometer at 266 nm3.
2.2.4.7. In vitro release kinetics. The data obtained from release
studies were ﬁtted into kinetic models like zero order, ﬁrst order,
Higuchi, Hixson Crowell, Korsemeyer-Peppas, to study the
mechanism of drug release from the prepared nanoparticles.
2.2.4.8. In vivo studies. In vivo studies were performed to deter-
mine the efﬁciency of prepared nanoparticles for effective brain
targeting. The studywas performed after obtaining the approval
from PSG Institutional Animal Ethics Committee RegistrationNo.: 158/99/CPCSEA. In vivo studies were performed on male
micewithweights of 30–35 g. The animalswere divided into four
groups with three animals in each group. Group 1 received the
drug solution, group 2 received formulation without any surface
modiﬁcation, group 3 received formulation with surface modiﬁ-
cation using tween 80, and group 4 was kept as control. The
doses were calculated based on body surface area.
After 60 min the animals were anesthetized and sacriﬁced
by using chloroform. The organs like brain, liver, kidney,
spleen were removed and washed with phosphate buffer saline
pH 7.4 and homogenized using tissue homogenizer for 15 min
by using 5 ml of phosphate buffered saline (pH 7.4). The
homogenates were stored in a deep freezer at 80 C until
use (Schaffazick et al., 2008).
2.2.4.9. Tissue sample preparation. 50 ll of tissue homogenate
was transferred to a clean test tube and 5 ll of the internal
standard was added (10 lg/ml of lamivudine) into tissue
homogenate and vortexed for 5 min. To each sample, 0.8 ml
of ethyl acetate was added and vortex-mixed for 5 min and
centrifuged at 10,000 RPM for 3 min at 4 C. 0.6 ml of organic
layer was separated and placed into a clean glass test tube and
evaporated to dryness under vacuum at 45 C in a concentra-
tor. The residue was reconstituted in 100 ll of mobile phase
and vortex-mixed for 3 min. The reconstituted samples were
injected for analysis (Tan and Douglas Boudinot, 2000).
2.2.4.10. HPLC conditions. HPLC was performed using waters
515 system equipped with a binary solvent delivery pump,
Rheodyne manual injector and UV detector (Waters 2489).
The chromatographic separation was performed on a C18 col-
umn: Luna C18, 100A (150 · 3.0 mm, 5 l) (Phenomenex) and
the absorbance was monitored at 266 nm. The system was
run in the isocratic mode with a mobile phase consisting of
methanol: potassium dihydrogen phosphate buffer (pH 3.0,
5 mM) in the ratio of 40:60 (v/v) and was delivered at a ﬂow
rate of 0.3 mL/min. The mobile phase was ﬁltered through a
0.22 lm Nylon ﬁlter (Pall Scientiﬁc, Ville St. Laurent, QC,
Canada) and degassed in an ultrasonic bath for 30 min prior
to use. The injection volume was 20 ll while the column was
maintained at room temperature during the run.
3. Results and discussion
3.1. DSC studies
DSC studies were performed to assess the nature of drug pres-
ent in the formulations and also to study the interaction
between excipients used, DSC studies were performed to ﬁnd out
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to determine the form in which the drug is entrapped in the nano-
particles. Fig. 1(A) and (B) depicts theDSCThermogram for zido-
vudine and zidovudine loaded nanoparticles respectively.
The drug zidovudine displayed a characteristic endothermic
peak at 125.8 C which is the melting point/transition temper-
ature for the drug clearly depicted in Fig. 1(A). DSC thermo-
gram of the drug loaded nanoparticles depicted in Fig. 1(B)
showed two endothermic peaks at 47.1 C and 125.1 C. The
peak at 47.1 C corresponds to the PLGA glass transition tem-
perature (Tg) and the peak at 125 C corresponds to the endo-
thermic peak of zidovudine respectively. The slight change in
drug endotherm was due to morphological changes attained
when formulated (Sunil et al., 2005).
3.2. Particle size
Particle size which is an important parameter for brain target-
ing has to be considered because particles lesser than 200 nmFigure 1 DSC Thermograms of (A) zare required for good targeting to the brain. Studies have
showed particles lesser than 100 nm are more effective in deliv-
ering drugs to the brain (Wilson et al., 2008).
The average mean particle size of the prepared nanoparti-
cles is summarized in Table 2, the mean particle size was found
to be in the range of 56 nm to 93 nm. The particle size in this
range is essential for the particle to reach the brain by evading
phagocytosis.
Formulation F9 was prepared by coating formulation F6
with tween 80 for the purpose of targeting, mean particle size
of F9 was found to be 83 nm. Smaller particles with a size
range below 100 nm with the hydrophilic surface were found
to have longer circulation in the blood, thus prolonging the
duration of therapeutic effect and improving targeting to the
desired sites (Banerjee et al., 2002).
The concentration of poloxamer 407 was found to inﬂuence
the particle size of the prepared nanoparticles which was in
accordance with the results obtained which described that
nanoparticles with a smaller size range and narrow sizeidovudine and (B) formulation F9.
Table 2 In vitro evaluation results of prepared formulations F1–F9.
F code Mean particle size (nm) Entrapment eﬃciency (%) Process yield (%) % drug release
F1 81 28.00 75.80 85.28 ± 0.80
F2 93 41.50 65.71 79.29 ± 0.35
F3 68 30.25 65.33 85.67 ± 0.67
F4 74 46.00 69.75 76.49 ± 0.28
F5 71 50.50 73.20 82.84 ± 1.20
F6 79 59.50 76.00 74.17 ± 0.67
F7 56 48.25 64.00 85.30 ± 1.03
F8 69 52.75 60.75 70.67 ± 1.73
F9 83 57.27 74.84 82.38 ± 1.34
Figure 3 TEM image of tween 80 coated formulation F9.
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tant concentration (Vauthier and Bouchemal, 2009).
In formulations with a low level of poloxamer F1, F2, F5
and F6, the particle size was found to be higher than prepara-
tions containing high concentrations F3, F4, F7 and F8 of the
poloxamer in both aqueous and acidic pH. This shows that the
particle size of the prepared nanoparticles was inﬂuenced by
the concentration of the poloxamer.
Formulation F7 comprising 100 mg of drug, 100 mg of
polymer and 100 mg of poloxamer was found to possess a
low mean particle size of 56 nm and formulation F2 with
100 mg drug, 200 mg polymer and 50 mg poloxamer has the
larger size of 93 nm. When PBS pH 7.4 was used as aqueous
phase it resulted in the aggregation of particles which could
not be measured.
The surface plot shown in Fig. 2 indicates the effect of pol-
oxamer and PLGA on the particle size of nanoparticles. This
proves that the polymer and stabilizer combination selected
have good suitability to use in the nanoprecipitation technique
to produce nanoparticles with a particle size below 100.
3.3. Surface morphology
Surface morphology of the prepared formulations was evalu-
ated by obtaining TEM images. TEM images were taken forFigure 2 Surface plot illustrating the inﬂuence of PLGA and
Poloxamer on particle size of the prepared formulations.formulation F9 and the images obtained proved the spherical
shape of the nanoparticles as shown in Fig. 3.
3.4. Zeta potential
Samples were diluted appropriately using Millipore water be-
fore the measurement of zeta potential. Zeta potential value
of formulation F9 was found to be – 20 mV. Zeta potential va-
lue is an important parameter which inﬂuences formulation
stability. Stability is very important to prevent settling of
nanoparticles.
3.5. Entrapment efﬁciency
Entrapment efﬁciency of formulations was in the range of 28–
59.5%. Entrapment efﬁciency was found to be inﬂuenced by
the amount of polymer and the pH of the aqueous phase. Ta-
ble 2 depicts the results obtained for the prepared formula-
tions. Formulation F6 containing 100 mg drug, 200 mg
polymers and 50 mg poloxamer was found to possess high
entrapment efﬁciency.
The formulations containing 200 mg of polymer in compo-
sition show higher entrapment than the formulations contain-
ing 100 mg of polymer. Formulations F1–F4 were found to
possess low entrapment efﬁciency and this may be due to
acidic pH of the aqueous medium (Govender et al., 1999). For-
mulations prepared with distilled water as external aqueous
phase show high entrapment than formulations prepared with
acidic medium as external aqueous phase. This shows the inﬂu-
ence of pH on the entrapment efﬁciency. Changes in aqueous
Figure 5 Cumulative mean % release of zidovudine from PLGA
nanoparticles containing poloxamer 407 in PBS pH 7.4.
Figure 6 Surface plot depicting the inﬂuence of PLGA and
poloxamer on drug release from PLGA nanoparticles.
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cles (Govender et al., 1999; Peltonen et al., 2004). The response
surface plot illustrating the effect of polymer PLGA and aque-
ous medium on the entrapment efﬁciency of nanoparticles is
shown in Fig. 4.
Change in pH of the medium results in diffusion of the drug
from the inner phase to outer phase which results in low
entrapment. This is due to the ionization of the drug at a par-
ticular pH which results in high solubility and this enhances
the drug to stay in aqueous phase while the molecular form
of drug stays in the hydrophobic polymer phase (Govender
et al., 1999).
3.6. Process yield
The process yield values for the prepared formulations are
summarized in Table 2. Process yield of the prepared formula-
tions ranged from 60.75% to 76%. Results are summarized in
Table 2. The yield was very low for F8 and F6 shows a good
process yield of 76%. Good yield shows good efﬁciency of
the preparation method. This shows the suitability of the
method to prepare formulations as the process yield was found
to be above 50% (Govender et al., 1999).
3.7. In vitro drug release
The cumulative percentage release of formulations F1–F8
ranges from 70.67 ± 1.73 to 85.67 ± 0.67, the values are pre-
sented in Table 2.
All formulations showed burst release initially clearly seen
in Fig. 5, followed by sustained release, burst release was
due to drug molecules adsorbed in the surface of nanoparticles.
These drug particles at the surface instantaneously dissolve
when it comes into contact with the medium (Agnihotri
et al., 2004).
Surface plot in Fig. 6 clearly shows the effect of formulation
variables PLGA and poloxamer on drug release. Amount of
PLGA affected the drug release, as the concentration of the
polymer increases, release decreases. Retardation of release
was more pronounced in formulations with 200 mg of polymerFigure 4 Surface plot depicting the inﬂuence of PLGA and
aqueous medium on entrapment efﬁciency of PLGA
nanoparticles.than formulations containing 100 mg of polymer. This was
clearly seen in formulations F2, F4, F6, and F8. The surface
plot clearly depicts the decrease in release with increase in
the amount of polymer. Poloxamer when used in high levels
delays release than its presence in low levels.
Release of drug from nano carriers is inﬂuenced by param-
eters that are drug related, polymer related and environmen-
tally related. The drug related parameters that inﬂuence
release are its molecular weight, concentration, interaction
with carrier, diffusion, ion exchange, desorption from surface,
position, and physicochemical properties.
The polymer related parameters are size and density of the
particle, amount and type of matrix material, denaturation of
polymerization, nature and extent of cross linking, presence of
excipients, surface erosion, total disintegration of particles and
surface erosion.
Environmentally related parameters are polarity, ionic
strength, presence of enzymes, light, magnetism, microwave
and temperature (Tomlinson, 1983).
The data obtained from in vitro release studies were ﬁtted
into release kinetic models like zero order, ﬁrst order, Higuchi,
Hixson Crowell and Korsemeyer Peppas. The values are pre-
sented in Table 3. The formulations were found to have higher
r2 values for the ﬁrst order model which shows that the release
Figure 7 Concentration of zidovudine (ng/ml) in various organs
on administration of the drug solution, F6 and F9.
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Higher r2 values were seen for the Higuchi model indicating
diffusion controlled release (Dhanalekshmi et al., 2010). The
n-value obtained after the Korsemeyer plot was in the range
of 0.56–0.76 indicating that release followed anomalous non
Fickian transport.
3.8. In vivo studies
Nanoparticles with sizes above 100 nm will tend to restrict
their biodistribution, they are cleared from systemic circulation
by Kupffer cells or other phagocytic cell populations within
the mononuclear phagocytic system. Table 4 shows concentra-
tion of zidovudine in tissues.
Higher concentration of zidovudine 2464.76 ± 43.22 was
observed in the brain when nanoparticles coated with tween
80 (formulation F9) were administered whereas the concentra-
tion of uncoated nanoparticles formulation F6 in the brain was
913.63 ± 11.45. The concentration of zidovudine achieved in
the brain when administered as plain drug solution was
352.33 ± 25.96.
These results show that more drug reaches the brain when
the formulation coated with tween 80 is administered which
was in accordance with results reported for doxorubicin and
loperamide by means of polysorbate 80 coated nanoparticles
and for dalargin (Gelperina et al., 2010; Kreuter et al.,
1997). The mechanism behind high transport of drugs to the
brain after coating with polysorbate 80 according to that it
was due to the adsorption of apolipoprotein B and E from
blood over the polysorbate 80 coated nanoparticles which fur-
ther enhances endocytosis mediated transport into the brain
(Kreuter et al., 2002).
The reason for the animal sacriﬁce and excision of organs
1 h after dosing was based on the result that maximum concen-
tration of zidovudine was at 1 h after the dose administrationTable 3 Determination coefﬁcient (r2) and diffusion exponent (n) a
F code Zero order First order Hixson C
r2 r2 r2
F1 0.8652 0.9787 0.9566
F2 0.8844 0.9743 0.9483
F3 0.8913 0.9416 0.9115
F4 0.8409 0.9869 0.965
F5 0.8852 0.9546 0.9398
F6 0.9104 0.9528 0.9271
F7 0.9123 0.9782 0.9518
F8 0.9056 0.9916 0.9747
F9 0.8589 0.8977 0.8747
Table 4 Zidovudine concentration (ng/ml) in different organs after
and zidovudine drug in solution.
S.No Organ F9
1. Brain 2464.76 ± 43.22
2. Plasma 11943.33 ± 34.26
3. Liver 7328.27 ± 30.53
4. Spleen 7904.61 ± 57.50
5. Kidney 5035 ± 57.64(Lobenberg et al., 1998). When compared to plain drug solu-
tion high concentration of the drug is seen in the brain with
formulation F6 containing uncoated nanoparticles and this
may be due to effect of particle size. Fig. 7 depicts the distribu-
tion of zidovudine to various organs.
Plasma concentration of coated formulation F9 was
11,943.33 ± 34.26 1 h after administration to animals and
for formulation F6 it was 12,635.67 ± 14, for the zidovudine
drug in solution it was 16,286.33 ± 38.52. Zidovudine plasma
concentration was less after the administration of formulations
F9 and F6 than the drug in solution and this may be due to the
slow release of the drug from the nanoparticles.
Concentration achieved in the liver after the administration
of Formulation F9, F6 and drug in solution was,
7328.27 ± 30.53, 8044.97 ± 76.43, and 5423.36 ± 67.25
respectively. Higher concentration of drug is seen in the liverfter ﬁtting the release data.
rowell Higuchi Korsmeyer Peppas
r2 r2 n
0.9813 0.8666 0.56
0.9783 0.8701 0.58
0.9799 0.8975 0.60
0.9686 0.9057 0.65
0.9618 0.9189 0.68
0.9872 0.9626 0.76
0.9813 0.8958 0.66
0.9877 0.9391 0.67
0.9803 0.9304 0.53
the administration of formulation F9, uncoated formulation F6
F6 Zidovudine
913.63 ± 11.45 352.33 ± 25.96
12635.67 ± 14 16286.33 ± 38.52
8044.97 ± 76.43 5423.36 ± 67.25
9508.31 ± 34.35 8584.96 ± 20.01
5680.81 ± 44.86 7679.3 ± 51.7
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to the uptake of nanoparticles by the reticuloendothelial sys-
tem especially by the kupffer cells (Plard and Bazile, 1999).
The concentrations of drug in the spleen were,
7904.61 ± 57.50, 9508.31 ± 34.35, and 8584.96 ± 20.01 for
coated formulation F9, uncoated formulation F6, and plain
drug in solution. The distribution of zidovudine to the spleen
reduced after coating with polysorbate 80 solution.
The drug concentration achieved in the kidney after the
administration of coated formulation F9 was 5035 ± 57.64,
for uncoated formulation it was 5680.81 ± 44.86 and for drug
in solution it was higher than formulations 7679.3 ± 51.7. The
diagramatic representation of the concentration of zidovudine
achieved in different organs is depicted in Fig. 7.
3.9. Stability determination of formulation F9 after 90 days
Stability of the prepared formulations was evaluated at room
temparature and in refrigerated condition for a period of
90 days. The formulations were evaluated for pH, particle size,
and appearance. The results proved that the formulations were
stable.
4. Conclusion
Zidovudine loaded PLGA nanoparticles were prepared suc-
cessfully by nanoprecipitation technique and coated with
tween 80 to achieve good concentration in the brain. The pre-
pared formulations were evaluated in vitro and in vivo. The re-
sults revealed that formulations were found to be spherical in
shape with good size distribution. It also possesses good
entrapment efﬁciency and prolonged release of the drug. The
in vivo results indicated that the formulations possess required
qualities to achieve good concentration in the brain. In vivo
studies in mice revealed that formulation coated with tween
80 achieved higher concentrations in the brain than formula-
tion with uncoated nanoparticles and drug in solution. Further
studies are required to improve the qualities of the formulation
and make it an efﬁcient drug delivery system.
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